Comparative assessment of drug-eluting balloons in an advanced porcine model of coronary restenosis

Summary

The advent of drug-eluting balloon (DEB) therapy has represented an important development in interventional cardiology. Nevertheless, pre-clinical data with this technology remain scant, and comparative studies have not previously been published. Bare metal stents were implanted in the coronary arteries of 15 pigs followed by balloon angioplasty. Animals were allocated to treatment with a 60-second inflation of one of four different balloon catheters: a conventional untreated plain angioplasty balloon (PBA, Biotronik AG), the Pantera Lux DEB (3.0 μg/mm² paclitaxel; BTHC excipient, Biotronik AG), the Elutax DEB (2.0 μg/mm² paclitaxel; no excipient; Aachen Resonance), or the SeQuent Please DEB (3.0 μg/mm² paclitaxel; iopromide excipient: B. Braun). Twenty-eight days following balloon deployment, animals underwent repeat angiography for quantitative coronary angiography analysis and euthanasia for histopathologic assessment. By histology, the mean neointimal thickness was 0.44 ± 0.19 mm with PBA, 0.35 ± 0.13 mm with Pantera Lux, 0.61 ± 0.20 mm with Elutax, and 0.47 ± 0.21 mm with SeQuent Please DEB (p=0.02). In comparison with PBA, deployment of the Pantera Lux or the SeQuent Please DEB resulted in delayed healing characterised by significant increases in fibrin, neointimal cell vacuity and delayed re-endothelialisation. In conclusion, investigation of comparative DEB performance in a porcine model of advanced coronary restenosis reveals significant heterogeneity of neointimal suppression between the devices tested with numerically lowest values seen in the Pantera Lux group. On the other hand, evidence of delayed healing was observed in the most effective DEB groups.

Keywords

Porcine model - drug-eluting balloon - restenosis

• References

• 1 Guzman LA, Mick MJ, Arnold AM. et al. Role of intimal hyperplasia and arterial remodeling after balloon angioplasty: an experimental study in the athero-sclerotic rabbit model. Arterioscler Thromb Vasc Biol 1996; 16 (03) 479-487.
• 2 Farb A, Sangiorgi G, Carter AJ. et al. Pathology of acute and chronic coronary stenting in humans. Circulation 1999; 99 (01) 44-52.
• 3 Morice MC, Serruys PW, Sousa JE. et al. A randomized comparison of a sirolimuseluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346 (23) 1773-1780.
• 4 Byrne RA, Sarafoff N, Kastrati A. et al. Drug-eluting stents in percutaneous coronary intervention: a benefit-risk assessment. Drug Saf 2009; 32 (09) 749-770.
• 5 Scheller B, Hehrlein C, Bocksch W. et al. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med 2006; 355 (20) 2113-2124.
• 6 Scheller B, Speck U, Abramjuk C. et al. Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation 2004; 110 (07) 810-814.
• 7 Dommke C, Haase KK, Suselbeck T. et al. Local paclitaxel delivery after coronary stenting in an experimental animal model. Thromb Haemost 2007; 98: 674-680.
• 8 Farb A, Tang AL, Shroff S. et al. Neointimal responses 3 months after (32)P beta-emitting stent placement. Int J Radiat Oncol Biol Phys 2000; 48 (03) 889-898.
• 9 Schwartz RS, Huber KC, Murphy JG. et al. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol 1992; 19: 267-274.
• 10 Joner M, Byrne RA. The importance of preclinical research in contemporary interventional cardiology. EuroIntervention 2010; 6: 19-23.
• 11 Cremers B, Speck U, Kaufels N. et al. Drug-eluting balloon: very short-term exposure and overlapping. Thromb Haemost 2009; 101: 201-206.
• 12 Cremers B, Biedermann M, Mahnkopf D. et al. Comparison of two different paclitaxel-coated balloon catheters in the porcine coronary restenosis model. Clin Res Cardiol 2009; 98: 325-330.
• 13 Poss J, Jacobshagen C, Ukena C. et al. Hotlines and clinical trial updates presented at the German Cardiac Society Meeting 2010: FAIR-HF, CIPAMI, LIPSIA-NSTEMI, Handheld-BNP, PEPCAD III, remote ischaemic conditioning, CERTIFY, PreSCD-II, German Myocardial Infarction Registry, DiaRegis. Clin Res Cardiol 2010; 99: 411-417.
• 14 Finn AV, Kolodgie FD, Harnek J. et al. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation 2005; 112: 270-278.
• 15 Joner M, Finn AV, Farb A. et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006; 48: 193-202.
• 16 Unverdorben M, Vallbracht C, Cremers B. et al. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation 2009; 119: 2986-2994.
• 17 Cortese B, Micheli A, Picchi A. et al. Paclitaxel-coated balloon versus drug-eluting stent during PCI of small coronary vessels, a prospective randomised clinical trial. The PICCOLETO study. Heart 2010; 96: 1291-1296.